

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 29, 2004

THE QUIGLEY CORPORATION

(Exact Name of Registrant as Specified in Charter)

NEVADA	01-21617	23-2577138
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Kells Building, 621 Shady Retreat Road, P.O. Box 1349, Doylestown, PA 18901

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (215) 345-0919

N/A

(Former Name or Former Address, if Changed Since Last Report.)

(more)

ITEM 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS.

On April 29, 2004, The Quigley Corporation announced its results for the quarter ended March 31, 2004. The full text of the press release is attached hereto as Exhibit 99.1.

Exhibits

99.1 First Quarter Preliminary Unaudited Earnings Release.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 29, 2004

THE QUIGLEY CORPORATION

By: /s/ George J. Longo

Name: George J. Longo
Title: Vice President and
Chief Financial Officer

3

CONTACT:

David K. Waldman/John W. Heilshorn
Lippert Heilshorn & Associates
(212) 838-3777
dwaldman@lhai.com

Carl Fonash
The Quigley Corporation
(267) 880-1111

QUIGLEY REPORTS FIRST QUARTER RESULTS
AND PROVIDES UPDATES ON PHARMACEUTICAL SEGMENT

DOYLESTOWN, PA. - APRIL 29, 2004 - THE QUIGLEY CORPORATION (NASDAQ: QGLY) today reported net sales of \$9.6 million for the first quarter of 2004, a 17.3% increase over the \$8.2 million reported for the same period in 2003.

The increase in net sales for the first quarter of 2004 reflects a 26.3% increase in the Company's Cold Remedy segment and a 11.3% increase in the Health and Wellness segment. The Company's Cold Remedy net sales continue to increase as a result of strategic advertising, marketing initiatives, and new products. The Company's Health and Wellness revenues have increased as distribution continues to expand internationally.

The Company also provided the following updates regarding its Ethical Pharmaceutical segment:

- - Quigley Pharma held its pre-IND meeting with the United States Food and Drug Administration regarding QR-333, the Company's patented formula for the topical treatment of diabetic peripheral neuropathy. The Company has received the necessary input from the United States Food and Drug Administration advising it as to the steps to be taken to progress towards pivotal phase III clinical trials.
- - Quigley Pharma demonstrated that its patent-applied-for formulation, QR-336, was protective against the effects of a lethal, whole body ionizing (nuclear) radiation dose, in a pre-clinical mouse model study. Based upon the findings of the pre-clinical radiation study of QR-336 in mice, the Company is preparing the necessary protocols to proceed to a GLP 'Good Laboratory Practice' controlled animal study.
- - Quigley Pharma demonstrated the virucidal and virustatic activity of QR-435 against the strain 3B of the Human Immunodeficiency Virus (HIV) Type 1 in an in-vitro study. Previous in-vitro and in-vivo studies have suggested that QR-435 also has broad anti-viral properties for applications such as Influenza A&B, SARS, and Herpes Simplex 1. Given the broad anti-viral properties of QR-435, the Company intends to embark on the FDA regulatory path for approval.

Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "Both our Cold Remedy and Health and Wellness segments continue to generate strong results, which helps offset the costs associated with our pharmaceutical research and development. We are encouraged by the improved sales of COLD-EEZE(R), especially within several large retail chains, as well as the strong performance of our honey lemon COLD-EEZE. Looking ahead, we plan to begin delivery of our new COLD-EEZE bubble gum and COLD-EEZE 'green-tea with lemon' lozenges to retail stores during the third quarter."

Loss from continuing operations for the first quarter of 2004 was \$782,000, or (\$0.07) per share, compared to a loss from continuing operations of \$892,000, or (\$0.08) per share, for the same period last year. Net loss for the first quarter ended March 31, 2004 was \$724,000, or (\$0.06) per share, compared to a net loss of \$947,000, or (\$0.08) per share, for the same period last year.

Loss from continuing operations for the quarter ended March 31, 2004 improved as compared with the same period last year, driven by gross profit gains, which were partially offset by increases in marketing, administrative, and research and development costs associated with Quigley Pharma and other clinical studies.

No tax benefits to reduce losses are provided for the quarters ended March 31, 2004 and 2003, since the Company is in a net operating loss carry-forward position, which is from the cumulative effect of deductions attributed to options, warrants and unrestricted stock from previous year's taxable income.

In January 2003, the company completed the sale of its 60% equity interest in Caribbean Pacific Natural Products, Inc. to Suncoast Naturals, Inc. by exchanging its 60% controlling interest in Caribbean Pacific Natural Products, Inc. for 750,000 Shares of Common Stock and 100,000 Shares of Redeemable Preferred Stock of Suncoast Naturals, Inc. The results of operations of Caribbean Pacific Natural Products, Inc. are reflected as discontinued operations of the Company for the periods presented. Net loss for the quarter

ended March 31, 2003 includes \$54,000 associated with discontinued operations of Caribbean Pacific Natural Products, Inc.

The Quigley Corporation (Nasdaq: QGLY, <http://www.Quigleyco.com>) is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (<http://www.QuigleyPharma.com>), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

(Tables Follow)

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

The following represents condensed financial data (in thousands) except loss from continuing operations per share and diluted net loss per share and weighted average shares outstanding for the periods presented:

	Three-Months Ended March 31, 2004 (\$)	Three-Months Ended March 31, 2003 (\$)
Net Sales	9,606	8,191
Gross profit	4,520	3,694
Sales & marketing expenses	1,623	1,527
Administrative expenses	2,750	2,442
Research & development	947	647
Income taxes (Benefit)	--	--
Loss from:		
Continuing operations	(782)	(892)
Discontinued operations	--	(55)
Cumulative effect of change in accounting principle	58	--
Net loss	(724)	(947)
Diluted loss per share:		
Continuing operations	(\$0.07)	(\$0.08)
Discontinued operations		
Cumulative effect of change in accounting principle	\$0.01	--
Net loss	(\$0.06)	(\$0.08)
Diluted weighted average common shares outstanding:	11,510,687	11,456,617

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

The following represents condensed financial data (in thousands) at March 31, 2004 and December 31, 2003:

	2004 (\$) -----	2003 (\$) -----
Cash & cash equivalents	15,587	11,392

Accounts receivable, net	2,078	7,862
Inventory	3,954	3,753
Total current assets	22,083	23,740
Total assets	24,585	26,270
Total current liabilities	4,509	5,483
Total stockholders' equity	20,077	20,787